ESMO Sarcoma and Rare Cancers 2023 | Utilizing NGS to identify molecular targets in advanced sarcoma

Antonia Digklia, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses how certain subtypes of advanced sarcoma with specific molecular modifications can be identified through next generation sequencing (NGS) and ultimately targeted in the neoadjuvant setting. Dr Digklia stresses, however, that international collaboration is necessary to test these rare cancer targets in a clinical trial context, as these approaches are not yet validated. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.